Jill Marie Broadfoot - Feb 5, 2024 Form 4 Insider Report for aTYR PHARMA INC (LIFE)

Role
Chief Financial Officer
Signature
/s/ Nancy E. Denyes, attorney-in-fact
Stock symbol
LIFE
Transactions as of
Feb 5, 2024
Transactions value $
-$2,687
Form type
4
Date filed
2/6/2024, 08:18 PM
Previous filing
Jan 9, 2024
Next filing
Jun 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LIFE Common stock Options Exercise +3.75K +20.1% 22.4K Feb 5, 2024 Direct F1, F2
transaction LIFE Common stock Sale -$2.69K -1.59K -7.09% $1.69 20.8K Feb 6, 2024 Direct F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LIFE Restricted Stock Unit Options Exercise $0 -3.75K -33.33% $0.00 7.5K Feb 5, 2024 Common Stock 3.75K Direct F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired upon the vesting of restricted stock units (RSUs) granted to the Reporting Person on February 3, 2022.
F2 Restricted stock units convert into common stock on a one-for-one basis.
F3 Sale made by the Reporting Person to satisfy tax withholding obligations in connection with the partial vesting of RSUs granted on February 3, 2022.
F4 The RSUs vest in four equal annual installments beginning on February 3, 2023, such that the RSUs will fully vest on February 3, 2026. The RSUs are subject to accelerated vesting upon termination without cause upon a change of control of the Issuer.